Skip to NavigationSkip to content

Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis

Published on 14/10/19 at 11:14am

Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and key secondary endpoints in a 12-week, Phase 3 study investigating its efficacy in the treatment of moderate to severe atopic dermatitis (AD) in patients aged 12 and older.

The findings revealed that 43.8% and 23.7% of patients achieved an Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin with 200mg and 100mg of abrocitinib respectively compared to placebo – one of the trial’s co-primary endpoints. For the other endpoint, 62.7% and 39.7% taking 200mg and 100mg of abrocitinib respectively achieved at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) score, compared to 11.8% with placebo.

Furthermore, 38.6% and 18.6% of 200mg and 100mg abrocitinib patients respectively achieved an EASI score of at least 90 compared to 5.3% for placebo, meeting a key secondary endpoint of the study.

The results were presented at the 28th Congress of the European Academy of Dermatology and Venereology (EADV) in Madrid.

“There is a critical need for additional treatment options for patients living with moderate to severe atopic dermatitis,” said Dr Michael Corbo, Chief Development Officer, Inflammation & Immunology, at Pfizer Global Product Development. “We are pleased by these findings, which together with the recently reported positive top-line results from our second Phase 3 trial, encourage us that, if approved, abrocitinib may provide the first oral, once-daily treatment option for these patients.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches